Market Chatter: CSL Secures Canada Pandemic Influenza Vaccine Supply Contract, AFR Says

MT Newswires Live03-05 10:26

CSL's (ASX:CSL) influenza vaccine unit, Seqirus, has secured a contract to supply 15 million doses of a cell-based adjuvanted pandemic flu vaccine from its new Melbourne facility if a pandemic is declared by the World Health Organization, according to a Thursday report by the Australian Financial Review.

CSL Seqirus has previously had a contract with Canada, under which it was required to provide an egg-based influenza vaccine in the event of a pandemic, the report added.

The company's shares rose almost 2% in recent Thursday trade.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment